InMed Pharmaceuticals (INM) 10% Owner LLC Buys $750 of Stock

ADAR1 Capital Management, LLC bought 564 shares of InMed Pharmaceuticals Inc. (NasdaqCM: INM) on October 13, 2026, for a total value of $750.12. The purchase price was $1.33 per share, and this transaction adds to ADAR1's existing holdings in the pharmaceutical developer.

Inside ADAR1 Capital Management's Trade

This recent purchase increases ADAR1's total holdings to 91,101 shares. The firm has been actively increasing its stake in InMed, with several prior transactions in recent weeks. This buy shows a sustained interest in the company's potential, particularly as it focuses on developing cannabinoid-based pharmaceuticals.

Other Institutional Activity in InMed Pharmaceuticals

ADAR1 Capital Management isn't the only institutional player in InMed Pharmaceuticals. Vivo Capital, LLC holds 798,377 shares worth about $1,053,857 after adding 399,188 shares. Squadron Capital Management LLC has also increased its stake, now holding 325,000 shares valued at approximately $429,000, following a 162,500 share increase. Additionally, Ikarian Capital, LLC and Ursa Fund Management, LLC have also boosted their positions significantly, both increasing their share counts by 100% in their last reports.

InMed Pharmaceuticals Inc. Stock Down 0.8%

As of October 16, 2026, InMed Pharmaceuticals was recently trading around $1.32, which is 43.3% below its 52-week high of $2.33. The stock is currently below its 50-day moving average of $1.38, but above its 52-week low of $0.57, reflecting a challenging market position. The recent trading levels suggest some volatility as the company continues to develop its product pipeline.

Recent Earnings

InMed Pharmaceuticals reported a trailing twelve-month revenue of $0, with a net margin of 0.0%. The company has been operating at a loss, reflected in its EPS of -$2.84. Investors will be looking for signs of recovery or growth in the upcoming earnings report scheduled for November 5, 2026.

Insider Buying and Selling at InMed Pharmaceuticals Inc.

Insider activity has been notable at InMed Pharmaceuticals. On October 8, 2026, Adar1 Capital Management purchased 10,903 shares at an average price of $1.33, totaling $14,484. Earlier, on October 5, it bought 42,920 shares for $57,080. This consistent buying trend indicates a strong belief in the company's future despite its current financial challenges. Other insiders, like Vivo Opportunity LLC, also bought 20,546 shares at $1.55 each on July 16, 2026.

Bottom Line

ADAR1 Capital Management's recent purchase adds to its growing stake in InMed Pharmaceuticals as the company prepares for its next earnings report on November 5, 2026. Investors will be watching closely to see how the company progresses in its drug development efforts and whether these insider moves translate into positive news for shareholders.